Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217823 | 0.81 | GPR119 (0.42) | L3MBTL1CYP24A1GPR119TBXAS1CYP17A1 | |
| SCHEMBL8149950 | 0.79 | HTT (0.40) | CYP24A1TBXAS1ALDH1A1LMNAAHR | |
| SCHEMBL5768859 | 0.78 | TBXAS1 (0.36) | CYP24A1TBXAS1ALDH1A1LMNAAHR | |
| SCHEMBL618874 | 0.76 | ALDH1A1 (0.43) | CYP24A1TBXAS1ALDH1A1LMNATDP1 | |
| SCHEMBL19185024 | 0.76 | QPCT (0.33) | L3MBTL1CYP24A1GPR119CYP17A1ALDH1A1 | |
| SCHEMBL2218227 | 0.75 | MAPT (0.46) | TBXAS1ALDH1A1AHRTDP1 | |
| SCHEMBL6415097 | 0.75 | AHR (0.35) | TBXAS1ALDH1A1AHRTDP1 | |
| SCHEMBL21367602 | 0.75 | L3MBTL1 (0.42) | L3MBTL1CYP24A1GPR119CYP17A1ALDH1A1 | |
| SCHEMBL18886277 | 0.74 | CYP19A1 (0.36) | L3MBTL1CYP24A1GPR119 | |
| SCHEMBL15025343 | 0.73 | L3MBTL1 (0.39) | L3MBTL1CYP24A1GPR119TBXAS1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| US-20080220536-A1 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates | ERIANSON DANIEL A | 2008-09-11 | — | — | US | disclosed |
| EP-1814883-A1 | BICYCLIC INHIBITORS OR RHO KINASE | Vertex Pharmaceuticals Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7214487-B2 | Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214487-B2 | Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214487-B2 | Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| EP-1062199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046236-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| US-5776964-A | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-07 | — | — | US | disclosed |
| EP-0627432-B1 | 6-Piperazinyl-1H-pyrazolo [3,4-b]pyridine-3-carboxylic Acids, Esters, Amides and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5521206-A | HYPOTENSIVE AGENTS, TREATMENT OF ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| EP-0627432-A1 | 6-Piperazinyl-1H-pyrazolo [3,4-b]pyridine-3-carboxylic Acids, Esters, Amides andrelated compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5300498-A | Treating depression, obsessive compulsive disorder | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-04-05 | — | — | US | disclosed |
| US-4810397-A | ALUMINUM COMPOUND, ACID, THIADIAZOLE OR TRIAZOLE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-03-07 | — | — | US | disclosed |
| US-4719001-A | ALUMINUM COMPOUND AND THIADIAZOLE DERIVATIVE | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | ROCK1, ROCK2, RHOA | L3MBTL1 2857/4885CYP24A1 4435/4885GPR119 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.